Bristol-Myers Squibb (NYSE:BMY) - Stock Price, News & Analysis

BMY Stock Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

About the company

BMY fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	5/6
Financial Health	3/6
Dividends	5/6

Rewards

Trading at 74.3% below our estimate of its fair value

Earnings are forecast to grow 11.39% per year

Earnings grew by 24.1% over the past year

Pays a reliable dividend of 4.65%

Trading at good value compared to peers and industry

Risk Analysis

Has a high level of debt

Bristol-Myers Squibb Company Competitors

Zoetis

NYSE:ZTS

US$82.7b

Pfizer

NYSE:PFE

US$172.2b

Merck

NYSE:MRK

US$258.1b

Johnson & Johnson

NYSE:JNJ

US$367.1b

Price History & Performance

Summary of all time highs, changes and price drops for Bristol-Myers Squibb
Historical stock prices
Current Share Price	US$49.02
52 Week High	US$81.44
52 Week Low	US$48.42
Beta	0.37
1 Month Change	-3.92%
3 Month Change	-22.00%
1 Year Change	-38.06%
3 Year Change	-21.44%
5 Year Change	-8.00%
Change since IPO	244.00%

Recent updates

Bristol-Myers Squibb: The Patent Expiry Challenge

Nov 23

Bristol Myers Squibb: Bright Future Ahead

Nov 17

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Nov 08

Bristol-Myers Squibb: Time To Get Greedy

Oct 21

Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud

Oct 09

Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years

Sep 26

Bristol Myers Squibb: Pharma And Government Playing 'Chicken' Over New Drug Pricing Rules

Sep 16

Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today

Sep 09

Bristol-Myers Squibb: Patents, Profits, And Prognosis

Aug 24

Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly

Aug 01

Bristol-Myers: Potentially Set To Soar And Too Cheap To Ignore

Jul 19

Bristol-Myers Squibb: Back In The Doldrums - Or Just Pausing For Breath?

Jul 06

Bristol Myers Squibb: Take The Red Pill

Jun 05

High Quality Dividend Growth Near 52-Week Lows: Bristol-Myers Squibb Is A Good Bet

May 30

Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today

May 21

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Apr 27

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.57

Apr 05

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.57

Mar 09

Bristol's Opdivo improves disease-free survival in urothelial carcinoma over long term

Feb 17

Shareholder Returns

	BMY	US Pharmaceuticals	US Market
7D	0.2%	-0.1%	0.1%
1Y	-38.1%	-3.1%	13.5%

Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned -3.1% over the past year.

Return vs Market: BMY underperformed the US Market which returned 13.5% over the past year.

Price Volatility

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	3.3%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

Stable Share Price: BMY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: BMY's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1887	34,300	Chris Boerner	https://www.bms.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Bristol-Myers Squibb Company Fundamentals Summary

How do Bristol-Myers Squibb's earnings and revenue compare to its market cap?
BMY fundamental statistics
Market Cap	US$101.25b
Earnings (TTM)	US$8.29b
Revenue (TTM)	US$44.94b

12.0x

P/E Ratio

2.2x

P/S Ratio

Is BMY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMY income statement (TTM)
Revenue	US$44.94b
Cost of Revenue	US$10.33b
Gross Profit	US$34.60b
Other Expenses	US$26.32b
Earnings	US$8.29b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 02, 2024

Earnings per share (EPS)	4.07
Gross Margin	77.01%
Net Profit Margin	18.44%
Debt/Equity Ratio	129.6%

How did BMY perform over the long term?

See historical performance and comparison

Dividends

4.7%

Current Dividend Yield

58%

Payout Ratio

BMY Stock Overview

Rewards

Risk Analysis

Bristol-Myers Squibb Company Competitors

NYSE:ZTS

US$82.7b

NYSE:PFE

US$172.2b

NYSE:MRK

US$258.1b

NYSE:JNJ

US$367.1b

Price History & Performance

Recent News & Updates

Bristol-Myers Squibb: The Patent Expiry Challenge

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb: Bright Future Ahead

Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Recent updates

Bristol-Myers Squibb: The Patent Expiry Challenge

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb: Bright Future Ahead

Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Bristol Myers Squibb Appoints Christopher Boerner as Chief Executive Officer

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol-Myers Squibb Company Revises Earnings Guidance for the Full Year 2023

Price target decreased by 8.2% to US$66.21

Third quarter 2023 earnings: EPS exceeds analyst expectations

Bristol-Myers Squibb: Time To Get Greedy

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 Checkmate -77T Trial

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Early Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types At Esmo2023

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Upcoming dividend of US$0.57 per share at 3.9% yield

Bristol-Myers Squibb Company to Report Q3, 2023 Results on Oct 26, 2023

Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company Declares Quarterly Dividend, Payable on November 1, 2023

Bristol Myers Squibb: Pharma And Government Playing 'Chicken' Over New Drug Pricing Rules

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

Bristol Myers Squibb Announces New Long-Term Follow-Up Results from Two Phase 3 Studies Evaluating CAMZYOS (Mavacamten)

Insider recently sold US$1.1m worth of stock

The Bristol Myers Squibb-Pfizer Announces Results from ATHENS

Insider notifies of intention to sell stock

Bristol-Myers Squibb: Patents, Profits, And Prognosis

Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

Bristol Myers Squibb to Showcase Data Across Its Innovative Cardiovascular Portfolio At the European Society of Cardiology Congress 2023

Bristol Myers Squibb Announces Updated Results from the Registrational TRIDENT-1 Study

Consensus EPS estimates fall by 17%

Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly

Bristol-Myers Squibb Company Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bristol-Myers: Potentially Set To Soar And Too Cheap To Ignore

Bristol-Myers Squibb: Back In The Doldrums - Or Just Pausing For Breath?

Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer At High Risk of Recurrence in Patients with Tumor Cell Pd-L1 Expression >=1%

Upcoming dividend of US$0.57 per share at 3.6% yield

Bristol Myers Squibb Receives European Commission Approval of CAMZYOS(R) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023

Bristol-Myers Squibb Company Announces U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label

Bristol Myers Squibb Announces Quarterly Dividend, Payable on August 1, 2023

Bristol-Myers Squibb Company to Report Q2, 2023 Results on Jul 27, 2023

Bristol Myers Squibb Announces Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Bristol Myers Squibb: Take The Red Pill

Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma

High Quality Dividend Growth Near 52-Week Lows: Bristol-Myers Squibb Is A Good Bet

Bristol Myers Squibb to Present First Results At ASCO and EHA from Phase 3 Commands Study of Reblozyl (Luspatercept-Aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes

Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis

Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

High number of new directors

Insider recently sold US$3.4m worth of stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations